Return to Homepage
Promoting Excellence in Education, Research, and Patient Care in the Rapidly Evolving Management of Gastrointestinal Cancer International Society of Gastrointestinal Oncology - Established 2003
About Us Highlights and News Conferences Contact Us
2012 ISGIO Conference
Program Description
Invited Faculty
Scientific Program
Registration Information
Call for Abstracts
Educational Grants
ISGIO 2011
2010 Meeting Review
2009 Meeting Review
2008 Meeting Review
ISGIO 2007 Meeting Information
2006 ISGIO Meeting Review
Click here for the 2007 registration form
Click here for the ISGIO registration form
Program Description
2011 Gastrointestinal Oncology Conference
Program Description
The 2012 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care.
 
Educational Objectives
After attending the Conference, participants will be able to:
b Identify recent advances and innovations in the treatment of GI malignancies within the past 12 months;
b Describe emerging evidence from current clinical trials that may impact treatment decision making in GI oncology;
b Formulate a multi-modal approach to the treatment of hepatocellular carcinoma;
b

Analyze how recent clinical trial data demonstrate a significant survival benefit with a combination chemotherapy regimen in patients with metastatic pancreatic cancer;
b Define which patients benefited the most based on the results of 2 large colon cancer trials demonstrated that the addition of cetuximab to chemotherapy improves outcomes for all patients with normal KRAS, regardless of BRAF status;
b Discuss the multicenter trial results that demonstrate that sunitinib, a multi-targeted TKI, may delay disease progression in patients with pancreatic neuroendocrine tumors, and contribute to increased survival;
b Name the prognostic value of 8 molecular markers on relapse-free survival and stages II and III colon cancer.
 
Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Johns Hopkins University School of Medicine and the International Society of Gastrointestinal Oncology. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
American Nurses Credentialing Center
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
 
 
©2011 International Society of Gastrointestinal Oncology